Drugs / carcinoembryonic antigen peptide 1-6D
carcinoembryonic antigen peptide 1-6D
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00057915 | Sep 2003 → Aug 2006 | cancer of unknown primary site | Duke University | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00012246 | Jul 2002 → Jul 2006 | bile duct cancer, colorectal cancer, esophageal cancer, gallbladder cancer +3 | The University of Texas Medical Branch, Galveston | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | carcinoembryonic antigen peptide 1-6D | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00012246 ↗ |
| Known as | CAP 1-6D | “Patients receive carcinoembryonic antigen peptide 1-6D (CAP 1-6D) emulsified in Montanide ISA-51 adjuvant subcutaneously on day 1.” NCT00012246 ↗ |
| Known as | CEA peptide 1-6D | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00057915 ↗ |
| Route | Subcutaneous | “Patients receive carcinoembryonic antigen peptide 1-6D (CAP 1-6D) emulsified in Montanide ISA-51 adjuvant subcutaneously on day 1.” NCT00012246 ↗ |